BRPI0506486A - derivados de piridìnio e quinolìnio - Google Patents

derivados de piridìnio e quinolìnio

Info

Publication number
BRPI0506486A
BRPI0506486A BRPI0506486-4A BRPI0506486A BRPI0506486A BR PI0506486 A BRPI0506486 A BR PI0506486A BR PI0506486 A BRPI0506486 A BR PI0506486A BR PI0506486 A BRPI0506486 A BR PI0506486A
Authority
BR
Brazil
Prior art keywords
pyridinium
blocking
diseases
compounds
parasitic
Prior art date
Application number
BRPI0506486-4A
Other languages
English (en)
Inventor
Sanjuan Juan Carlos Lacal
Rosa Joaquin Campos
Meza Miguel Angel Gallo
Ubeda Antonio Espinosa
Original Assignee
Consejo Superior Investigacion
Univ Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Univ Granada filed Critical Consejo Superior Investigacion
Publication of BRPI0506486A publication Critical patent/BRPI0506486A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"DERIVADOS DE PIRIDìNIO E QUINOLìNIO". A invenção provê compostos bloqueadores de biossíntese de fosforilcolina da fórmula I por meio do bloqueamento seletivo da enzima de quinase de colina em células de tumor ou em células afetadas por infecções parasitárias sendo então aplicáveis no tratamento de tumores e doenças parasitárias ou doenças produzidas por vírus e fungos em animais, incluindo seres humanos; bem como um método para preparar os compostos da invenção e certos intermediários do dito método.
BRPI0506486-4A 2004-01-14 2005-01-11 derivados de piridìnio e quinolìnio BRPI0506486A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400072A ES2237332B1 (es) 2004-01-14 2004-01-14 Derivados de piridinio y quinolinio.
PCT/ES2005/070002 WO2005068429A1 (es) 2004-01-14 2005-01-11 Derivados de piridinio y quinolinio

Publications (1)

Publication Number Publication Date
BRPI0506486A true BRPI0506486A (pt) 2007-02-13

Family

ID=34778265

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506486-4A BRPI0506486A (pt) 2004-01-14 2005-01-11 derivados de piridìnio e quinolìnio

Country Status (16)

Country Link
US (1) US7781458B2 (pt)
EP (2) EP1710236B1 (pt)
JP (2) JP5047627B2 (pt)
KR (1) KR101157206B1 (pt)
CN (1) CN1910153B (pt)
AT (1) ATE461918T1 (pt)
BR (1) BRPI0506486A (pt)
CA (1) CA2553328C (pt)
DE (1) DE602005020112D1 (pt)
DK (1) DK1710236T3 (pt)
ES (2) ES2237332B1 (pt)
HK (1) HK1100441A1 (pt)
MX (1) MXPA06007940A (pt)
PL (1) PL1710236T3 (pt)
PT (1) PT1710236E (pt)
WO (1) WO2005068429A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586613B2 (en) * 2004-01-14 2013-11-19 Universidad De Granada Pyridinium and quinolinium derivatives
CA2729857A1 (en) 2008-07-04 2010-01-07 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
US20110212994A1 (en) * 2009-06-26 2011-09-01 Brian Clem Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders
WO2012041493A1 (en) * 2010-09-28 2012-04-05 Julius-Maximilians-Universität Würzburg Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
JP2014527397A (ja) 2011-06-20 2014-10-16 トラスラショナル、キャンサー、ドラッグス、ファーマ、ソシエダッド、リミターダＴｒａｓｌａｔｉｏｎａｌ Ｃａｎｃｅｒ Ｄｒｕｇｓ Ｐｈａｒｍａ， Ｓ．Ｌ． 癌患者の化学療法に対する臨床応答を予測する方法
KR20140069204A (ko) * 2011-09-22 2014-06-09 버텍스 파마슈티칼스 인코포레이티드 콜린 키나제의 억제제로서 유용한 화합물
ES2472367B1 (es) * 2012-12-28 2015-06-02 Universidad De Granada Inhibidores no simétricos de colina quinasa con actividad antitumoral y antimalárica
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
ES2482290B1 (es) * 2014-06-05 2015-05-19 Universidad De Granada Inhibidores polares simétricos de colina cinasa con actividad antitumoral
CN109790164B (zh) 2016-07-25 2022-01-25 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
EP3652177A1 (en) 2017-07-11 2020-05-20 Nerviano Medical Sciences S.r.l. Pyrazolo-quinazoline derivatives as choline kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206215A (en) * 1976-02-25 1980-06-03 Sterling Drug Inc. Antimicrobial bis-[4-(substituted-amino)-1-pyridinium]alkanes
GB1533952A (en) * 1976-02-25 1978-11-29 Sterling Drug Inc Anti-microbial bis-pyridinium compounds
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL89026A (en) * 1988-01-29 1993-02-21 Lilly Co Eli Substituted quinolines and cinnolines, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
ES2117950B1 (es) * 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.

Also Published As

Publication number Publication date
JP5047627B2 (ja) 2012-10-10
ES2237332A1 (es) 2005-07-16
MXPA06007940A (es) 2007-01-23
ES2343418T3 (es) 2010-07-30
EP1710236B1 (en) 2010-03-24
WO2005068429A1 (es) 2005-07-28
JP5619805B2 (ja) 2014-11-05
KR20060110364A (ko) 2006-10-24
EP1710236A1 (en) 2006-10-11
EP2085386A3 (en) 2009-10-28
ATE461918T1 (de) 2010-04-15
JP2012149077A (ja) 2012-08-09
CA2553328A1 (en) 2005-07-28
PL1710236T3 (pl) 2010-08-31
DE602005020112D1 (de) 2010-05-06
CN1910153B (zh) 2010-05-26
CA2553328C (en) 2012-05-15
ES2237332B1 (es) 2006-11-01
EP2085386A2 (en) 2009-08-05
US20070185170A1 (en) 2007-08-09
KR101157206B1 (ko) 2012-07-06
JP2007517837A (ja) 2007-07-05
DK1710236T3 (da) 2010-07-12
HK1100441A1 (en) 2007-09-21
PT1710236E (pt) 2010-06-18
CN1910153A (zh) 2007-02-07
US7781458B2 (en) 2010-08-24

Similar Documents

Publication Publication Date Title
BRPI0506486A (pt) derivados de piridìnio e quinolìnio
UA116187C2 (uk) ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
BRPI0506736A (pt) composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
WO2006113942A3 (en) Method of inhibiting cathepsin activity
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BR112012016111A2 (pt) Composto hererocíclico contendo nitrogênio, fungicida agrícola, e, produto intermediário
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
ATE408601T1 (de) Fredericamycin-derivate
EP1740581A4 (en) PYRIDYL DERIVATIVE COMPOUNDS SUBSTITUTED AT POSITIONS 2, 4, 6 USEFUL AS INHIBITORS OF BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
EA200801372A1 (ru) Способы получения замещенных пиримидинов
HK1166465A1 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as parp inhibitors for use in treating cancer
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
BRPI0516904A (pt) processo para a preparação de um derivado de 2-etilaminopiridina e composto
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
DE602005017626D1 (de) Antivirale verwendung von borinsäurekomplexen
EA200801108A1 (ru) Триазолы, пригодные для лечения воспалений
EA200801107A1 (ru) Пиразолы, пригодные для лечения воспалений
WO2006133928A3 (en) Use of phenylsemicarbazones for seed treatment
WO2006118973A3 (en) Methods of using heterobyclic compounds for treatment of rectal cancer
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]